Impact of empagliflozin on insulin needs in patients with heart failure and diabetes: An <scp>EMPEROR‐Pooled</scp> analysis

Empagliflozin exerts a consistent benefit on cardiovascular outcomes and renal function decline, irrespective of baseline insulin use, and reduces the need for sustained insulin initiation in patients with HF and diabetes.